M. Kupari et al., CONGESTIVE-HEART-FAILURE IN OLD-AGE - PREVALENCE, MECHANISMS AND 4-YEAR PROGNOSIS IN THE HELSINKI AGING STUDY, Journal of internal medicine, 241(5), 1997, pp. 387-394
Objective. To examine the prevalence, underlying diseases, abnormaliti
es of left ventricular function and prognosis in congestive heart fail
ure (CHF) of old age. Design. A population-based clinical and echocard
iographic study with a 4-year mortality followup. Setting. University
hospital. Subjects, Five hundred and one individuals born in 1904, 190
9 and 1914 (367 women). Main outcome measures. Presence of CHF by clin
ical and chest radiograph criteria; left ventricular size and systolic
function by echocardiography; grade of aortic and mitral valve lesion
s by Doppler echocardiography; 4-year total and cardiovascular mortali
ty. Results. Forty-one of 501 participants (8.2%) had CHF. Ischaemic h
eart disease (54%), hypertension (54%) and moderate-to-severe mitral o
r aortic valve disease (51%) were the main underlying conditions; 90%
of patients had one or more of these diseases. Most individuals with C
HF (28 of 39 patients, 72%) had normal left ventricular contractions a
t echocardiography. 'Diastolic CHF', defined as CHF with normal systol
ic left ventricular function and no regurgitant valve disease, was fou
nd in 51% (20 of 39 patients). The relative 4-year risk for death asso
ciated with CHF, adjusted for age and sex, was 2.1 (95% confidence int
erval 1.3-3.4) for all-cause mortality and 4.2 (CI 1.9-5.6) for cardio
vascular mortality. Conclusions. The prevalence of CHF in a population
aged 75-86 years is approximately 8%. Ischaemic or valvular heart dis
ease and hypertension are the main underlying conditions. At echocardi
ography, about 50% of the elderly with CHF have normal left ventricula
r systolic contractions in the absence of valve disease and an additio
nal 20% have normal systolic function with mitral regurgitation. The p
resence of CHF doubles the age- and sex-adjusted risk of death from al
l causes, and quadruples the risk of cardiovascular death during 4-yea
r follow-up.